Clinical Trial Update: A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates that the CAP-002 gene therapy trial in pediatric STXBP1-related encephalopathy (a developmental and epileptic encephalopathy) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Developmental and Epileptic Encephalopathy
• Stxbp1-related Encephalopathy

Drugs mentioned

• CAP-002 gene therapy

Snippet

Sponsor: Capsida Biotherapeutics, Inc. | Conditions: Developmental and Epileptic Encephalopathy | Phase 1, Phase 2 | Status: SUSPENDED